0001209191-21-033817.txt : 20210518 0001209191-21-033817.hdr.sgml : 20210518 20210518202217 ACCESSION NUMBER: 0001209191-21-033817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210514 FILED AS OF DATE: 20210518 DATE AS OF CHANGE: 20210518 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heyman Richard A. CENTRAL INDEX KEY: 0001584759 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39269 FILM NUMBER: 21938079 MAIL ADDRESS: STREET 1: 5871 OBERLIN DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001796280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471787157 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 388-5600 MAIL ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-14 0 0001796280 Oric Pharmaceuticals, Inc. ORIC 0001584759 Heyman Richard A. C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2021-05-14 4 S 0 3215 25.3133 D 223885 I See footnote Common Stock 2021-05-17 4 S 0 498 25.0679 D 223387 I See footnote Common Stock 2021-05-18 4 S 0 2161 25.3195 D 221226 I See footnote Common Stock 12500 D The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. Represents the weighted average share price of an aggregate total of 3,215 shares sold in the price range of $25.00 to $25.83 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Represents the weighted average share price of an aggregate total of 498 shares sold in the price range of $25.00 to $25.14 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 2,161 shares sold in the price range of $25.00 to $25.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Exhibit 24 - Power of Attorney /s/ Christian Kuhlen, attorney-in-fact 2021-05-18 EX-24 2 attachment1.htm EX-24 DOCUMENT



                                  POWER OF ATTORNEY

       The undersigned, as a Section 16 reporting person of Oric
Pharmaceuticals, Inc. (the "Company"), hereby constitutes and appoints Jacob
Chacko, Dominic Piscitelli, and Christian Kuhlen, and each of them, as the
undersigned's true and lawful attorney-in-fact to:

     1.     prepare, execute in the undersigned's name and on the undersigned's
            behalf, and submit to the Securities and Exchange Commission
            (the "SEC") a Form ID, including amendments thereto, and any other
            documents necessary or appropriate to obtain EDGAR codes and
            passwords enabling the undersigned to make electronic filings with
            the SEC of reports required by Section 16(a) of the Securities
            Exchange Act of 1934 or any rule or regulation of the SEC;

     2.     complete and execute Forms 3, 4 and 5 and other forms and all
            amendments thereto as such attorney-in-fact shall in his discretion
            determine to be required or advisable pursuant to Section 16 of the
            Securities Exchange Act of 1934 (as amended) and the rules and
            regulations promulgated thereunder, or any successor laws and
            regulations, as a consequence of the undersigned's ownership,
            acquisition or disposition of securities of the Company; and

     3.     do all acts necessary in order to file such forms with the SEC, any
            securities exchange or national association, the Company and such
            other person or agency as the attorneys-in-fact shall deem
            appropriate.

       The undersigned hereby ratifies and confirms all that said
attorneys in-fact and agents shall do or cause to be done by virtue hereof.  The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange
Act of 1934 (as amended).

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 29th day of April, 2021.


                                   Signature:  /s/ Richard A. Heyman
                                              -----------------------------
                                   Print Name:  Richard A. Heyman
                                               ----------------------------